Modifying stem cells shows initial promise in battle against muscular dystrophy
Myotonic dystrophy type 1 causes muscles in the face, neck, and lower arms and legs to get weak and shrink. Muscles that drive the heart and control breathing can weaken as the disease progresses. The two types of myotonic dystrophy affect 1 of every 8,000 people worldwide and there are no treatments to slow the diseases’ progression, according to the National Institutes of Health. The UF team used genome editing to repair the coding errors in human cells that cause myotonic dystrophy type 1, according to findings published recently in the journal Stem Cells.
During gene editing, researchers inserted a signal to truncate the RNA in the gene in adult stem cells. That blocked the abnormally long, repetitive stretches of RNA that cause myotonic dystrophy type 1. The gene editing reversed the abnormalities found in cells affected by myotonic dystrophy, said Xia, lead author of the paper.
“We know the gene that’s involved and we know what’s going on with it. If you can block the expression of the mutation then that’s the cure,” he said.
While much work remains for researchers before the therapy could be considered for testing in people, these findings are a first step that shows the DM1 genetic mutation can be altered to block the effects of mutation in cultured cells, said Laura Ranum, Ph.D., director of the College of Medicine’s Center for NeuroGenetics, a professor in the department of molecular genetics and microbiology and a co-author of the paper.
If additional studies are successful, this ability to genetically modify stem cells could someday lead to cell transfer therapy as a treatment for myotonic dystrophy type 1 and other neurological and neuromuscular disorders that develop in similar ways, Xia said.
Most read news
Organizations
Other news from the department science
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.